Siewick Director, Cancer Research
Director of Melanoma Research and Therapeutics
Co-Director Melanoma and Skin Cancer Center
Inova Schar Cancer
Dr. Sekwon Jang is a specialty care physician board certified in internal medicine, hematology, and medical oncology. He has a special interest in management of melanoma and other skin cancers including cutaneous lymphoma.
Dr. Jang serves as Director of Melanoma and Cutaneous Oncology Therapeutics and Research and Director of Quality at the Inova Schar Cancer Institute. Before joining Inova, Dr. Jang served as Assistant Professor of Medicine at Georgetown University School of Medicine and Co-Chair of melanoma research group at MedStar Georgetown Cancer Network.
Dr. Jang believes in a covenant relationship with his patients, and his goal is to provide the best quality patient-centered care in the setting of multidisciplinary collaboration.
Awards/Associations
- Member, American Society of Clinical Oncology
- Member, Society for Immunotherapy of Cancer
- Member, The Society for Melanoma Research
- Associate Professor, Department of Medicine, Virginia Commonwealth University
- Honor Award, Korean Academy of Medical Science
- Merit Award, American Society of Clinical Oncology
- Travel Award, American Society of Hematology
- Member, Quality of Care Committee, American Society of Clinical Oncology
- Top Doctors, Washingtonian, 2022
Research and Publications
View list of publications from Dr. Jang's research
Blog Posts
Early Study Finds MGC018 Active in Resistant Skin Cancer. July 2021.
Inova Melanoma Symposium Offers Resources and Hope. June 2018.
Education and Inspiration at Inova's First Melanoma Patient Symposium. June 2016.
New Findings in Cancer Immunotherapy: Inova Experts Weigh In. March 2016.
Experts from Inova Schar Cancer Institute's Melanoma and Skin Cancer Center Speak at Largest Annual Meeting of Dermatologists. March 2016.
Yervoy®: A New Option for Patients with Stage III Melanoma after Surgery. November 2015.
Cold Sore Virus as Melanoma Treatment. November 2015.
Immunotherapies Offer New Hope for Melanoma Patients. October 2015.
Patient Reviews
About Patient Comments
The Patient Rating score is an average of all responses to physician related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.